HCM
IMDZ

Highbridge Capital Management’s Immune Design Corp. IMDZ Stock Holding History

Highbridge Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-26,452
Closed -$215K – 1943
2016
Q2 		$215K Buy
+26,452
New +$330K ﹤0.01% 1210

Other funds holding IMDZ

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Highbridge Capital Management's IMDZ Position: Q3 2016 in Review

Highbridge Capital Management sold out of Immune Design Corp. (IMDZ) in Q3 2016, closing a stake of 26,452 shares — an estimated $215K sold.

Highbridge Capital Management first reported a position in IMDZ in Q2 2016 and held it in 1 quarter. The position peaked at $215K in Q2 2016. 59 funds tracked by Wall St. Rank hold IMDZ as of Q3 2016.

  • Highbridge Capital Management reported no remaining Immune Design Corp. position as of Q3 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 26,452 Immune Design Corp. shares in Q3 2016, an estimated $215K.
  • Highbridge Capital Management first reported a position in Immune Design Corp. in Q2 2016 and held it in 1 quarter.
  • Highbridge Capital Management's Immune Design Corp. position peaked at $215K in Q2 2016.
  • 59 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2016.

Based on Highbridge Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.